rifapentine (Priftin)
Jump to navigation
Jump to search
Indications
Contraindications
- not approved for children < 12 years of age
- ok for use in patients with HIV1 infection[3]
Dosage
- weekly in combination with isoniazid (latent tuberculosis)
- 10-14 kg: 300 mg weekly
- 14-25 kg: 450 mg weekly
- 25-32 kg: 600 mg weekly
- 32-50 kg: 750 mg weekly
- > 50 kg: 900 mg weekly
Tabs: 150 mg
Pharmacokinetics
- esterase hydrolysis with fecal elimination
elimination via plasma
Adverse effects
- urine, body secretions may turn orange
- may discolor contact lenses
- hepatitis
- rash
- dyspepsia
Drug interactions
- avoid use with antiretroviral protease inhibitors
- induces cyt P450s CYP2C9 & CYP3A4
- may diminish levels of drugs metabolized by CYP2C9 & CYP3A4
- drug interaction(s) anticonvulsants with anti-bacterial agents
- drug interaction(s) of antibiotics with warfarin
More general terms
Additional terms
References
- ↑ Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Schechter M et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006 Apr 15; 173:922-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16474028
- ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 17, 19. American College of Physicians, Philadelphia 2015, 2021